Half of Americans Believe only the Rich Can Afford GLP-1s without Insurance

Why It Matters

The high out‑of‑pocket cost limits access to effective obesity treatments, driving disparities and pressuring insurers and policymakers to address pricing and coverage gaps.

Key Takeaways

• Median household spends 7.3% on Ozempic monthly.
• Lowest‑income states face up to 10% income share.
• Half of aware Americans think only rich can afford.
• 60% of users pay $100+ out‑of‑pocket monthly.
• 55% would use Ozempic if fully covered by insurance.

Pulse Analysis

The steep price of GLP‑1 medications like Ozempic is reshaping the U.S. health‑care cost landscape. While the list price hovers around $349 for lower doses, a median‑income family would need to devote roughly 7 percent of its earnings each month, and residents of states such as Mississippi could see the drug consume more than 10 percent of household income. These figures not only strain personal budgets but also ripple into employer‑provided health plans, where insurers cite GLP‑1 demand as a factor behind rising premiums for 2026.

Consumer perception amplifies the financial pressure. Over half of Americans recognize GLP‑1 drugs, and among those, 50 percent view them as a luxury only the wealthy can afford. The data show that 60 percent of current users pay $100 or more out‑of‑pocket each month, prompting many to delay initiation, skip doses, or discontinue therapy altogether. This affordability gap fuels a broader equity concern, as nearly four in ten adults are either using, have used, or are considering these treatments, yet cost barriers curtail consistent access.

Looking ahead, insurance coverage and policy interventions could alter the trajectory. Approximately 55 percent of informed consumers—especially millennials—say they would adopt Ozempic if fully covered, prompting employers to weigh drug inclusion as a talent‑attraction tool. Meanwhile, the federal government plans to cap Medicare and Medicaid payments at $245 per month for GLP‑1s starting in 2027, and the emergence of generic versions may further depress prices. These developments suggest a potential narrowing of the affordability divide, though the pace and extent of coverage expansion will determine whether broader segments of the population can benefit from these clinically proven weight‑loss therapies.